SG11202002384VA - Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof - Google Patents
Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereofInfo
- Publication number
- SG11202002384VA SG11202002384VA SG11202002384VA SG11202002384VA SG11202002384VA SG 11202002384V A SG11202002384V A SG 11202002384VA SG 11202002384V A SG11202002384V A SG 11202002384VA SG 11202002384V A SG11202002384V A SG 11202002384VA SG 11202002384V A SG11202002384V A SG 11202002384VA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- bispecific
- activatable
- methods
- activatable antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572468P | 2017-10-14 | 2017-10-14 | |
| US201762577140P | 2017-10-25 | 2017-10-25 | |
| US201862613358P | 2018-01-03 | 2018-01-03 | |
| US201862666065P | 2018-05-02 | 2018-05-02 | |
| US201862731622P | 2018-09-14 | 2018-09-14 | |
| PCT/US2018/055717 WO2019075405A1 (fr) | 2017-10-14 | 2018-10-12 | Anticorps, anticorps activables, anticorps bispécifiques, et anticorps activables bispécifiques et leurs procédés d'utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002384VA true SG11202002384VA (en) | 2020-04-29 |
Family
ID=64308799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002384VA SG11202002384VA (en) | 2017-10-14 | 2018-10-12 | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11472889B2 (fr) |
| EP (1) | EP3694885A1 (fr) |
| JP (2) | JP7438106B2 (fr) |
| KR (1) | KR20200064096A (fr) |
| CN (1) | CN111247171A (fr) |
| AU (1) | AU2018347607A1 (fr) |
| BR (1) | BR112020007309A2 (fr) |
| CA (1) | CA3078911A1 (fr) |
| IL (1) | IL273937A (fr) |
| SG (1) | SG11202002384VA (fr) |
| TW (1) | TWI850203B (fr) |
| WO (1) | WO2019075405A1 (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2918795A1 (fr) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Anticorps multispecifiques, anticorps activables multispecifiques et leurs methodes d'utilisation |
| CA2955947A1 (fr) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispecifiques, anticorps anti-cd3 activables multispecifiques et procedes d'utilisation de ces anticorps |
| AU2018347607A1 (en) * | 2017-10-14 | 2020-03-26 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| EP3788077A1 (fr) * | 2018-05-02 | 2021-03-10 | CytomX Therapeutics, Inc. | Anticorps, anticorps activables, anticorps bispécifiques, et anticorps activables bispécifiques et leurs méthodes d'utilisation |
| ES2955511T3 (es) | 2018-05-14 | 2023-12-04 | Werewolf Therapeutics Inc | Polipéptidos de interleucina 2 activables y métodos de uso de los mismos |
| EP3794023A1 (fr) | 2018-05-14 | 2021-03-24 | Werewolf Therapeutics, Inc. | Polypeptides d'interleukine 12 activables et procédés d'utilisation associés |
| KR20220023988A (ko) | 2019-05-14 | 2022-03-03 | 웨어울프 세라퓨틱스, 인크. | 분리 모이어티 및 이의 사용 방법 |
| CN114423499A (zh) * | 2019-06-06 | 2022-04-29 | 佳努克斯治疗公司 | 与肿瘤激活的t细胞衔接子相关的组合物和方法 |
| CN113015749B (zh) * | 2019-09-30 | 2022-01-21 | 和铂医药(苏州)有限公司 | 靶向cd3的抗体、双特异性抗体及其用途 |
| EP4058471A1 (fr) | 2019-11-14 | 2022-09-21 | Werewolf Therapeutics, Inc. | Polypeptides de cytokine activables et leurs méthodes d'utilisation |
| MX2022012592A (es) | 2020-04-10 | 2022-12-07 | Cytomx Therapeutics Inc | Construcciones de citocinas activables y composiciones y metodos relacionados. |
| US20230322953A1 (en) | 2020-06-30 | 2023-10-12 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| MX2023001788A (es) | 2020-08-11 | 2023-04-26 | Janux Therapeutics Inc | Composiciones y metodos de enlazadores escindibles. |
| AU2021352532A1 (en) * | 2020-09-29 | 2023-05-25 | Fortvita Biologics (Singapore) Pte.Ltd. | Anti-claudin18.2 and cd3 bispecific antibody and use thereof |
| JP2023550148A (ja) | 2020-11-20 | 2023-11-30 | シンシア・イノベーション・インコーポレイテッド | がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法 |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| WO2022135536A1 (fr) * | 2020-12-25 | 2022-06-30 | 江苏先声药业有限公司 | Anticorps cd3 humanisé et son utilisation |
| WO2022170619A1 (fr) * | 2021-02-11 | 2022-08-18 | Adagene Pte. Ltd. | Anticorps anti-cd3 et leurs méthodes d'utilisation |
| KR20230157448A (ko) | 2021-03-16 | 2023-11-16 | 싸이톰스 테라퓨틱스, 인크. | 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법 |
| EP4403572A1 (fr) * | 2021-09-13 | 2024-07-24 | Shandong Simcere Biopharmaceutical Co., Ltd. | Anticorps anti-cd3 humain et son utilisation |
| MX2024004564A (es) | 2021-10-15 | 2024-04-30 | Cytomx Therapeutics Inc | Complejo polipeptidico activable. |
| WO2023064955A1 (fr) | 2021-10-15 | 2023-04-20 | Cytomx Therapeutics, Inc. | Complexe polypeptidique bispécifique hétéromultimère, anti-cd3, anti-egfr, activable |
| TW202330611A (zh) | 2021-10-15 | 2023-08-01 | 美商賽特艾克斯生物製藥公司 | 可活化之多肽複合物 |
| CN113980143B (zh) * | 2021-11-02 | 2023-04-25 | 深圳先进技术研究院 | 靶向cd276的嵌合抗原受体、嵌合抗原受体t细胞及制备方法和制药应用 |
| AU2023215789A1 (en) * | 2022-02-04 | 2024-08-01 | Zytox Therapeutics Ab | Fusion protein comprising an egfr-binding domain and a masking domain |
| WO2023183888A1 (fr) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Constructions de protéines de liaison à l'antigène activables et leurs utilisations |
| WO2023183923A1 (fr) | 2022-03-25 | 2023-09-28 | Cytomx Therapeutics, Inc. | Molécules masquées à double ancrage activables et leurs procédés d'utilisation |
| CN119300859A (zh) | 2022-04-01 | 2025-01-10 | 西托姆克斯治疗公司 | 可激活多特异性分子和其使用方法 |
| EP4504782A2 (fr) | 2022-04-01 | 2025-02-12 | CytomX Therapeutics, Inc. | Protéines de liaison au cd3 et leurs procédés d'utilisation |
| AR130078A1 (es) | 2022-08-01 | 2024-10-30 | Cytomx Therapeutics Inc | Substratos escindibles por proteasas, y métodos de uso de los mismos |
| TW202423953A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割部分及其使用方法 |
| TW202424183A (zh) | 2022-08-01 | 2024-06-16 | 美商Ｃｙｔｏｍｘ生物製藥公司 | 蛋白酶可切割受質及其使用方法 |
| WO2024030843A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Fractions clivables par protéase et leurs procédés d'utilisation |
| WO2024030847A1 (fr) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Fractions clivables par protéase et procédés d'utilisation associés |
| WO2024104988A1 (fr) * | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Protéines de liaison recombinantes ayant un domaine effecteur activable |
| WO2024216194A1 (fr) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Polypeptides de masquage, constructions de cytokine activables, compositions et procédés associés |
| WO2024216170A2 (fr) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Constructions de cytokine activables et compositions et procédés associés |
| WO2024216146A1 (fr) | 2023-04-12 | 2024-10-17 | Cytomx Therapeutics, Inc. | Polypeptides de masquage, constructions de cytokine activables, compositions et méthodes associées |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| WO1988001513A1 (fr) | 1986-08-28 | 1988-03-10 | Teijin Limited | Complexe d'anticorps cytocide et procede de production |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| PT752248E (pt) | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| IT1271461B (it) | 1993-12-01 | 1997-05-28 | Menarini Ricerche Sud Spa | Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso. |
| PL199659B1 (pl) | 1998-02-25 | 2008-10-31 | Merck Patent Gmbh | Białko fuzyjne przeciwciała hu-KS IL2, cząsteczka DNA kodująca białko fuzyjne przeciwciała hu-KS IL2 i sposób wytwarzania białka fuzyjnego przeciwciała hu-KS IL2 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| CA2326389C (fr) | 1998-04-21 | 2007-01-23 | Micromet Gesellschaft Fur Biomedizinische Forschung Mbh | Polypeptides specifiques a cd19 et cd3 et leurs utilisations |
| MX353234B (es) | 1999-01-15 | 2018-01-08 | Genentech Inc | Variantes de polipeptidos con función efectora alterada. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| MXPA02007733A (es) | 2000-02-11 | 2004-09-10 | Merck Patent Gmbh | Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos. |
| WO2001091798A2 (fr) | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers |
| AU2001293995B2 (en) | 2000-10-09 | 2005-10-13 | Cytomx Therapeutics, Inc. | Therapeutic antibodies |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US20030150294A1 (en) | 2002-01-25 | 2003-08-14 | Njall Stefansson | Filters for filtering molten metals and alloys field |
| EP1517921B1 (fr) | 2002-06-28 | 2006-06-07 | Domantis Limited | Ligands a specificite double et avec une demi-vie augmentee |
| US20040109855A1 (en) | 2002-07-23 | 2004-06-10 | Herman Waldmann | Therapeutic antibodies with reduced side effect |
| US8809504B2 (en) | 2002-09-03 | 2014-08-19 | Vit Lauermann | Inhibitor which is deactivatable by a reagent produced by a target cell |
| WO2005047461A2 (fr) | 2003-08-18 | 2005-05-26 | The Regents Of The University Of California | Bibliotheques d'affichage de polypeptides et procede de fabrication et d'utilisation de celle-ci |
| ES2403055T3 (es) | 2004-04-13 | 2013-05-13 | F. Hoffmann-La Roche Ag | Anticuerpos anti-P-selectina |
| SG10201606980VA (en) | 2004-06-03 | 2016-10-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| WO2007027935A2 (fr) | 2005-08-31 | 2007-03-08 | The Regents Of The University Of California | Bibliotheques cellulaires de sequences peptidiques (clips) et procedes d'utilisation de celles-ci |
| CA2625440C (fr) | 2005-10-11 | 2023-06-13 | Micromet Ag | Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations |
| WO2007105027A1 (fr) | 2006-03-10 | 2007-09-20 | Diatos | Médicaments anticancéreux conjugués à un anticorps au moyen d'un lieur dissociable par une enzyme |
| KR101516823B1 (ko) | 2006-03-17 | 2015-05-07 | 바이오겐 아이덱 엠에이 인코포레이티드 | 안정화된 폴리펩티드 조성물 |
| KR20090021298A (ko) | 2006-06-14 | 2009-03-02 | 임클론 시스템즈 인코포레이티드 | 항-ｅｇｆｒ 항체의 동결건조 제제 |
| SG195609A1 (en) | 2007-04-03 | 2013-12-30 | Amgen Res Munich Gmbh | Cross-species-specific binding domain |
| AU2008234019B2 (en) | 2007-04-03 | 2014-05-29 | Amgen Research (Munich) Gmbh | Cross-species-specific bispecific binders |
| TWI570135B (zh) | 2007-04-27 | 2017-02-11 | 建南德克公司 | 高效、穩定且非免疫抑制之抗－ｃｄ４抗體 |
| WO2009014726A1 (fr) | 2007-07-26 | 2009-01-29 | The Regents Of The University Of California | Procédés permettant d'améliorer un affichage de cellules bactériennes de protéines et de peptides |
| US20090155275A1 (en) | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| CA2697032C (fr) | 2007-08-22 | 2021-09-14 | The Regents Of The University Of California | Polypeptides de liaison activables et procedes d'identification et utilisation de ceux-ci |
| SI2250279T1 (sl) | 2008-02-08 | 2016-10-28 | Medimmune, Llc | Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda |
| NZ591134A (en) | 2008-10-01 | 2012-08-31 | Micromet Ag | Cross-species-specific (human and primate) bispecific single chain antibody that binds both cd3 (epsilon) epitope and prostate specific membrane antigen (pmsa) |
| US10981998B2 (en) | 2008-10-01 | 2021-04-20 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| EA032828B1 (ru) | 2008-10-10 | 2019-07-31 | Аптево Рисёрч Энд Девелопмент Ллс | Иммунотерапевтические средства против комплекса tcr |
| WO2010077643A1 (fr) | 2008-12-08 | 2010-07-08 | Tegopharm Corporation | Ligands de masquage pour inhibition réversible de composés polyvalents |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| BRPI1006141B8 (pt) | 2009-01-12 | 2021-05-25 | Cytomx Therapeutics Llc | composições de anticorpo modificado, métodos para preparar e usar as mesmas |
| JP5861223B2 (ja) | 2009-02-23 | 2016-02-16 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | プロタンパク質およびその使用方法 |
| EP2427479B1 (fr) | 2009-05-07 | 2018-11-21 | The Regents of The University of California | Anticorps et procédés d'utilisation de ceux-ci |
| IL300733A (en) | 2010-03-05 | 2023-04-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeting immune modulation |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| KR101612999B1 (ko) | 2010-08-24 | 2016-04-15 | 로슈 글리카트 아게 | 활성화가능 이중특이적 항체 |
| CA2822288A1 (fr) | 2010-12-22 | 2012-06-28 | Medimmune, Llc | Fragments et anticorps anti-c5/c5a/c5adesr |
| HUE041335T2 (hu) | 2011-03-29 | 2019-05-28 | Roche Glycart Ag | Antitest FC-variánsok |
| CN107903325B (zh) | 2011-05-16 | 2021-10-29 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
| RS58765B1 (sr) * | 2011-05-21 | 2019-06-28 | Macrogenics Inc | Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3 |
| HUE038225T2 (hu) | 2011-08-23 | 2018-10-29 | Roche Glycart Ag | Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák |
| WO2013026837A1 (fr) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t. |
| CN103781801B (zh) | 2011-08-23 | 2018-02-09 | 罗切格利卡特公司 | 包含两个Fab片段的无Fc的抗体及使用方法 |
| CA2844540C (fr) | 2011-08-23 | 2018-10-16 | Roche Glycart Ag | Anticorps bispecifiques specifiques pour les antigenes d'activation des lymphocytes t et un antigene tumoral et procedes d'utiliation correspondants |
| WO2013092001A1 (fr) | 2011-12-19 | 2013-06-27 | Synimmune Gmbh | Molécule d'anticorps bispécifique |
| GB201203442D0 (en) | 2012-02-28 | 2012-04-11 | Univ Birmingham | Immunotherapeutic molecules and uses |
| MX350312B (es) | 2012-03-14 | 2017-09-01 | Levicept Ltd | Uso terapeutico de la proteina de union a neurotrofina del receptor neutrofico p75. |
| US9120853B2 (en) | 2012-04-27 | 2015-09-01 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| KR20150037857A (ko) | 2012-06-22 | 2015-04-08 | 싸이톰스 테라퓨틱스, 인크. | 항-jagged 1/jagged 2 교차-반응성 항체, 활성화가능한 항-jagged 항체 및 이의 제조 방법 |
| US9856314B2 (en) | 2012-06-22 | 2018-01-02 | Cytomx Therapeutics, Inc. | Activatable antibodies having non-binding steric moieties and methods of using the same |
| SG10201605703TA (en) | 2012-07-06 | 2016-09-29 | Genmab Bv | Dimeric protein with triple mutations |
| WO2014012085A2 (fr) | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Hétérodimères asymétriques bispécifiques comprenant des produits de recombinaison anti-cd3 |
| IN2015DN01361A (fr) | 2012-08-02 | 2015-07-03 | Jn Biosciences Llc | |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| CN104271602B (zh) * | 2012-11-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 双特异性抗体 |
| ES2862950T3 (es) | 2012-12-18 | 2021-10-08 | Univ Rockefeller | Anticuerpos anti-CD4 modificados con glicanos para la prevención y terapia del VIH |
| WO2014107599A2 (fr) | 2013-01-04 | 2014-07-10 | Cytomx Therapeutics, Inc. | Compositions et procédés de détection d'une activité protéase dans des systèmes biologiques |
| DK2943511T3 (da) | 2013-01-14 | 2019-10-21 | Xencor Inc | Nye heterodimeriske proteiner |
| CA2897987A1 (fr) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Elimination rapide de complexes antigeniques a l'aide de nouveaux anticorps |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| MX357011B (es) | 2013-03-15 | 2018-06-22 | Amgen Inc | Anticuerpos biespecificos heterodimericos. |
| WO2014186842A1 (fr) | 2013-05-22 | 2014-11-27 | Monash University | Anticorps et leurs utilisations |
| AU2014274982B2 (en) | 2013-06-04 | 2019-12-05 | Cytomx Therapeutics, Inc | Compositions and methods for conjugating activatable antibodies |
| DK3016681T5 (da) * | 2013-07-05 | 2020-05-04 | Genmab As | Humaniserede eller kimære CD3-antistoffer |
| WO2015006482A1 (fr) | 2013-07-09 | 2015-01-15 | Duke University | Certaines molécules améliorées engageant les anticorps egfrviii bispécifiques humains |
| CA2918795A1 (fr) | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Anticorps multispecifiques, anticorps activables multispecifiques et leurs methodes d'utilisation |
| KR20160099081A (ko) | 2013-07-26 | 2016-08-19 | 업데이트 파마 인코포레이트 | 비산트렌의 치료 효과 개선용 조합 방법 |
| EP3733710A1 (fr) | 2013-09-25 | 2020-11-04 | Amgen, Inc | Anticorps v-c-fc-v-c hétérodimeriques |
| WO2015066279A2 (fr) | 2013-10-30 | 2015-05-07 | Cytomx Therapeutics, Inc. | Anticorps activables se liant au récepteur du facteur de croissance épidermique et méthodes d'utilisation de ceux-ci |
| BR112016017649B1 (pt) | 2014-01-31 | 2024-01-30 | Cytomx Therapeutics, Inc | Polipeptídeo isolado compreendendo substratos de matriptase e de ativador do plasminogênio u e outras porções cliváveis, composição farmacêutica compreendendo o dito polipeptídeo, bem como métodos para produzir e fabricar um polipeptídeo isolado compreendendo uma porção clivável e uso da composição farmacêutica e quantidade terapeuticamente eficaz da dita composição no tratamento de um distúrbio ou doença |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US9212225B1 (en) | 2014-07-01 | 2015-12-15 | Amphivena Therapeutics, Inc. | Bispecific CD33 and CD3 binding proteins |
| CA2955947A1 (fr) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anticorps anti-cd3, anticorps anti-cd3 activables, anticorps anti-cd3 multispecifiques, anticorps anti-cd3 activables multispecifiques et procedes d'utilisation de ces anticorps |
| AU2015323313B2 (en) | 2014-09-25 | 2021-04-01 | Amgen Inc. | Protease-activatable bispecific proteins |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| CN107207610B (zh) | 2014-11-26 | 2022-09-09 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| AR103488A1 (es) | 2015-01-23 | 2017-05-10 | Sanofi Sa | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 |
| MX2017012805A (es) | 2015-04-07 | 2018-04-11 | Genentech Inc | Complejo de unión a antígenos con actividad agonista y métodos de uso. |
| CN114507283A (zh) | 2015-05-04 | 2022-05-17 | 西托姆克斯治疗公司 | 抗cd71抗体、可活化抗cd71抗体及其使用方法 |
| EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| AU2017233121B2 (en) | 2016-03-15 | 2023-12-21 | Itabmed (Hk) Limited | Multispecific Fab fusion proteins and use thereof |
| AU2017237376B2 (en) | 2016-03-22 | 2024-03-07 | F. Hoffmann-La Roche Ag | Protease-activated T cell bispecific molecules |
| AU2018347607A1 (en) * | 2017-10-14 | 2020-03-26 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| EP3788077A1 (fr) | 2018-05-02 | 2021-03-10 | CytomX Therapeutics, Inc. | Anticorps, anticorps activables, anticorps bispécifiques, et anticorps activables bispécifiques et leurs méthodes d'utilisation |
-
2018
- 2018-10-12 AU AU2018347607A patent/AU2018347607A1/en active Pending
- 2018-10-12 CA CA3078911A patent/CA3078911A1/fr active Pending
- 2018-10-12 CN CN201880068235.0A patent/CN111247171A/zh active Pending
- 2018-10-12 EP EP18803495.3A patent/EP3694885A1/fr active Pending
- 2018-10-12 TW TW107136021A patent/TWI850203B/zh active
- 2018-10-12 KR KR1020207011417A patent/KR20200064096A/ko not_active Application Discontinuation
- 2018-10-12 JP JP2020520212A patent/JP7438106B2/ja active Active
- 2018-10-12 WO PCT/US2018/055717 patent/WO2019075405A1/fr active Application Filing
- 2018-10-12 SG SG11202002384VA patent/SG11202002384VA/en unknown
- 2018-10-12 US US16/159,451 patent/US11472889B2/en active Active
- 2018-10-12 BR BR112020007309-1A patent/BR112020007309A2/pt unknown
-
2020
- 2020-04-12 IL IL273937A patent/IL273937A/en unknown
-
2022
- 2022-09-07 US US17/930,143 patent/US11859010B2/en active Active
-
2023
- 2023-10-11 JP JP2023176130A patent/JP2024009935A/ja active Pending
- 2023-11-13 US US18/507,167 patent/US20240150492A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240150492A1 (en) | 2024-05-09 |
| CA3078911A1 (fr) | 2019-04-18 |
| BR112020007309A2 (pt) | 2020-09-29 |
| US11472889B2 (en) | 2022-10-18 |
| WO2019075405A1 (fr) | 2019-04-18 |
| JP2020536549A (ja) | 2020-12-17 |
| TW201927816A (zh) | 2019-07-16 |
| US20190135943A1 (en) | 2019-05-09 |
| US20230050083A1 (en) | 2023-02-16 |
| US11859010B2 (en) | 2024-01-02 |
| TWI850203B (zh) | 2024-08-01 |
| AU2018347607A1 (en) | 2020-03-26 |
| JP7438106B2 (ja) | 2024-02-26 |
| KR20200064096A (ko) | 2020-06-05 |
| EP3694885A1 (fr) | 2020-08-19 |
| CN111247171A (zh) | 2020-06-05 |
| IL273937A (en) | 2020-05-31 |
| JP2024009935A (ja) | 2024-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273937A (en) | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof | |
| IL270921A (en) | Activatable anti-PDL1 antibodies and methods of using them | |
| HK1250033A1 (zh) | 抗-pd-1抗體、可活化的抗-pd-1抗體、及其使用方法 | |
| HK1250036A1 (zh) | 抗cd 166抗體，可活化抗cd 166抗體及其使用方法 | |
| HK1250037A1 (zh) | 抗-itga3抗體、可活化的抗-itga3抗體、及其使用方法 | |
| IL272703A (en) | Activatable anti-CD166 antibodies and methods of using them | |
| IL254458A0 (en) | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies and methods of using them | |
| HK1250035A1 (zh) | 抗cd 71抗體，可活化抗cd 71抗體及其使用方法 | |
| ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
| PL3618863T3 (pl) | Przeciwciała anty- tigit i sposoby ich zastosowania | |
| IL275070A (en) | FCRN antibodies and methods of using them | |
| IL269645B1 (en) | Bispecific anti-CD37 antibodies, monoclonal anti-CD37 antibodies and methods of using them | |
| IL274221A (en) | Antibodies to ANTI-APOC3 and methods of use | |
| IL271346A (en) | Bispecific antibodies and methods for their preparation and use | |
| ZA202002144B (en) | Antibodies and methods of use |